• 1
    Freedland SJ, Presti JC Jr., Amling CL, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003; 61: 736741.
  • 2
    Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 1994; 152(5 Pt. 2): 18211825.
  • 3
    Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997; 24: 395406.
  • 4
    Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001; 28: 555565.
  • 5
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281: 15911597.
  • 6
    Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol. 1998; 160(6 Pt. 2): 24282434.
  • 7
    Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 1994; 152(5 Pt. 2): 18371842.
  • 8
    Moul JW, Connelly RR, Lubeck DP, et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol. 2001; 166: 13221327.
  • 9
    BeahrsOH, HensonDE, HutterRVP, MyersMH editors. AJCC cancer staging manual. 4th ed. Philadelphia: J.B. Lippincott Co., 1992: 181186.
  • 10
    Gleason DF, The Veterans Adminstrative Cooperative Urological Research Group. Histological grading and clinical staging of prostatic carcinoma. In: TannenbaumM, editor. Urologic pathology: the prostate. Philadelphia: Lea & Febiger, 1977: 171198.
  • 11
    Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am. 1993; 20: 713725.
  • 12
    Ravery V. The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Semin Urol Oncol. 1999; 17: 127129.
  • 13
    Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol. 2001; 165: 11461151.
  • 14
    Moul JW. Variables in predicting survival based on treating “PSA-only” relapse. Urol Oncol. 2003; 21: 292304.
  • 15
    Ts'o PO, Pannek J, Wang ZP, Lesko SA, Bova GS, Partin AW. Detection of intact prostate cancer cells in the blood of men with prostate cancer. Urology. 1997; 49: 881885.
  • 16
    Wang ZP, Eisenberger MA, Carducci MA, Partin AW, Scher HI, Ts'o PO. Identification and characterization of circulating prostate carcinoma cells. Cancer. 2000; 88: 27872795.
  • 17
    Terstappen LW, Rao C, Gross S, et al. Flow cytometry—principles and feasibility in transfusion medicine. Enumeration of epithelial derived tumor cells in peripheral blood. Vox Sang. 1998; 74(Suppl. 2): 269274.
  • 18
    Terstappen LW, Rao C, Gross S, Weiss AJ. Peripheral blood tumor cell load reflects the clinical activity of the disease in patients with carcinoma of the breast. Int J Oncol. 2000; 17: 573578.
  • 19
    Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000; 164: 101105.
  • 20
    Patel A, Dorey F, Franklin J, deKernion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997; 158: 14411445.
  • 21
    Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001; 76: 576581.
  • 22
    Partin AW, Pearson JD, Landis PK, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994; 43: 649659.
  • 23
    Khan MA, Partin AW. Management of high-risk populations with locally advanced prostate cancer. Oncologist. 2003; 8: 259269.
  • 24
    Khan MA, Walsh PC, Miller MC, et al. Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy. Cancer. 2003; 98: 25832591.
  • 25
    D'Amico AV, Renshaw AA, Arsenault L, Schultz D, Richie JP. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy. Int J Radiat Oncol Biol Phys. 1999; 45: 841846.